A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
Interventions: DRUG: irinotecan
Sponsor: Liaoning Tumor Hospital & Institute